PNC-28 (20mg)
PNC-28 is a synthetic anticancer peptide that has been studied primarily for its tumor-selective, pro-apoptotic effects — meaning it’s designed to selectively kill cancer cells while leaving healthy cells largely unaffected. It was originally developed at the State University of New York at Buffalo as part of experimental cancer therapy research.
$250.00
This product remains in its original powdered state without being reconstituted.
What is PNC-28 (20mg)?
What is PNC-28?
PNC-28 is a synthetic peptide derived from the p53 protein’s mdm-2 binding domain, specifically residues 17–26. It incorporates a cell-penetrating sequence, facilitating its entry into cells. Upon internalization, PNC-28 binds to the HDM-2 protein located on the plasma membrane of cancer cells, leading to the formation of membrane pores and subsequent necrosis of the tumor cells. This mechanism allows PNC-28 to selectively target and eliminate cancer cells without affecting normal, healthy cells.
1. Anticancer Activity
-
Selectively targets cancer cells by binding to membrane-associated p53 proteins, which are often mutated or misfolded in tumors.
-
Induces rapid apoptosis (programmed cell death) in cancer cells through mitochondrial disruption and membrane permeabilization.
-
Minimal toxicity to normal cells, as healthy cells typically express properly folded p53 localized in the nucleus rather than at the membrane.
2. Mechanism of Action
-
PNC-28 contains a p53-derived sequence fused to a membrane-penetrating peptide (derived from the antimicrobial peptide magainin).
-
Once inside tumor cells, it disrupts cell membrane integrity, leading to cell lysis and death.
-
It does not rely on immune system activation or DNA damage — its effect is direct and membrane-dependent.
3. Experimental and Preclinical Findings
-
Demonstrated tumor regression in several animal models (pancreatic, colon, and melanoma tumors).
-
Reduced tumor growth and increased survival rates in mice treated with intratumoral or systemic PNC-28.
-
Studies suggest a broad spectrum of activity across various solid tumor types that express abnormal p53.
4. Safety and Limitations
-
Preclinical data show low systemic toxicity and minimal side effects in healthy tissues.
-
Still experimental — not FDA-approved or widely available for human clinical use.
-
Further research is needed to confirm long-term safety, dosing, and pharmacokinetics.
Summary
PNC-28 is an experimental tumor-targeting peptide that works by selectively destroying cancer cells through a unique p53-dependent membrane mechanism. It represents a promising direction in peptide-based anticancer therapeutics but remains under investigation and is not yet approved for clinical treatment.
PRODUCTS ARE FOR RESEARCH PURPOSES ONLY
Related Products
Related products
